By Julius Musungu
Global Pharmaceutical Firm, Cipla, is expected to Locally roll out Remdevisir, one of the drugs approved by the US Food and Drug Association for the treatment of COVID 19 at a cost of Kshs 6000.
The drug will be shipped into the Kenyan market by the end of July courtesy of a deal between Gilead Sciences inc.who developed it and nine other pharmaceutical firms including Cipla.
Cipla Ltd Kenya in a statement said that Authorisation has already been filed to Kenya’s regulator Pharmacy and Poisons Board on July 17th.
“We filed on Friday and expect an answer within 14Days. We hope to have in stock before the end of July” the statement reads.
Once authorized the Drug will sell at Kshs 6000 which is about 55$.
Commercial Head of Cipla in Sub-Saharan Africa Martin Sweeny said the pricing is to ensure everyone in need has access to the medication.
“Inasmuch way that Cipla Pioneered affordable medication at the Height of the HIV Crisis about 2 decades ago and helped to save lives, we are committed to helping find a solution in the fight against this unprecedented global pandemic,” Sweeny said.
Sweeny said the production of the Drug had already started in preparation for the authorization by the Pharmacy and Poisons Board.
The Drug is administered intravenously for 5days at 200mg on the first day and later 100mg the next four days.
“Ita 5 Day Course which can be prolonged to 10 days depending on the condition of the Patient.
The statement reads.